ArticleClinical cancer research : an official journal of the American Association for Cancer Research2014
The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.Carcinogenesis · 2016Trial
- The landscape of NNature genetics · 2025Article
- Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.The Journal of urology · 2024Article
- Cumulative Effect Assessment of Common Genetic Variants on Prostate Cancer: Preliminary Studies.Biomedicines · 2022Article
- Identifying cancer tissue-of-origin by a novel machine learning method based on expression quantitative trait loci.Frontiers in oncology · 2022Article
- KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.Scientific reports · 2021Article
- Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.Cancer immunology, immunotherapy : CII · 2021Article
- Review
- Genome-wide association study of serum prostate-specific antigen levels based on 1000 Genomes imputed data in Japanese: the Japan Multi-Institutional Collaborative Cohort Study.Nagoya journal of medical science · 2021Article
- Proteomic Profiling of Two Distinct Populations of Extracellular Vesicles Isolated from Human Seminal Plasma.International journal of molecular sciences · 2020Article
- Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.Carcinogenesis · 2020Article
- Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients.Journal of clinical medicine · 2020Article
- Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.BMC medical genetics · 2020Article
- Application of Artificial Intelligence/Machine Vision & Learning for the Development of a Live Single-cell Phenotypic Biomarker Test to Predict Prostate Cancer Tumor Aggressiveness.Reviews in urology · 2020Article
- Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.Oncotarget · 2018Article
- Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer.Oncology letters · 2017Article
- Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.BMC cancer · 2017Article
- Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC).International journal of epidemiology · 2016Article
- Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Molecular diagnosis & therapy · 2016Review
- Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer.Oncotarget · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
purposeGleason score (GS) 7 prostate cancer is a heterogeneous disease with different clinical behavior. We sought to identify genetic biomarkers that may predict the aggressiveness of GS 7 diseases. EXPERIMENTAL
designWe genotyped 72 prostate cancer susceptibility SNPs identified in genome-wide association studies in 1,827 white men with histologically confirmed prostate adenocarcinoma. SNPs associated with disease aggressiveness were identified by comparing high-aggressive (GS ≥8) and low-aggressive (GS ≤6) cases. The significant SNPs were then tested to see whether they could further stratify GS 7 prostate cancer.
resultsThree SNPs-rs2735839, rs10486567, and rs103294-were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer (P < 0.05). Furthermore, the frequency of the variant allele (A) at rs2735839 was significantly higher in patients with biopsy-proven GS 4+3 disease than in those with GS 3 + 4 disease (P = 0.003). In multivariate logistic regression analysis, patients carrying the A allele at rs2735839 exhibited a 1.85-fold (95% confidence interval, 1.31-2.61) increased risk of being GS 4 + 3 compared with those with GS 3 + 4. The rs2735839 is located 600 base pair downstream of the KLK3 gene (encoding PSA) on 19q13.33 and has been shown to modulate PSA level, providing strong biologic plausibility for its association with prostate cancer aggressiveness.
conclusionsWe confirmed the association of the rs2735839 with high-aggressive prostate cancer (GS ≥8). Moreover, we reported for the first time that rs2735839 can stratify GS 7 patients, which would be clinically important for more accurately assessing the clinical behavior of the intermediate-grade prostate cancer and for tailoring personalized treatment and posttreatment management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.